Mersana Therapeutics, Inc. Forecast, price target & analysts
Mersana Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Mersana Therapeutics, Inc. Classifications & Recommendation:
Mersana Therapeutics, Inc. Price Target
| Target Price | $140.25 |
| Price | $8.11 |
| Potential |
1,629.35%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Mersana Therapeutics, Inc. 2026 .
The average Mersana Therapeutics, Inc. target price is $140.25.
This is
1,629.35%
register free of charge
$341.25
4,107.77%
register free of charge
$8.08
0.37%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Mersana Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Mersana Therapeutics, Inc. stock has an average upside potential 2026 of
1,629.35%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 40.50 | 23.24 |
| 9.88% | 42.62% | |
| EBITDA Margin | -177.06% | -500.39% |
| 61.48% | 182.61% | |
| Net Margin | -170.84% | -13.11% |
| 63.32% | 92.33% |
10 Analysts have issued a sales forecast Mersana Therapeutics, Inc. 2025 . The average Mersana Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Mersana Therapeutics, Inc. EBITDA forecast 2025. The average Mersana Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Mersana Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Mersana Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -14.12 | -0.61 |
| 61.80% | 95.68% | |
| P/E | negative | |
| EV/Sales | negative |
10 Analysts have issued a Mersana Therapeutics, Inc. forecast for earnings per share. The average Mersana Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Mersana Therapeutics, Inc....
Current Mersana Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | May 16 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 27 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Feb 06 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 27 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
